Gilead to Presents P-III (TROPiCS-02) Study Results of Trodelvy (sacituzumab govitecan) for Pre-Treated HR+/HER2- Metastatic Breast Cancer at ASCO 2023
- The P-III study (TROPiCS-02) evaluating Trodelvy vs CT in a ratio (1:1) in 543 patients with HR+/HER2- metastatic breast cancer who progressed on endocrine-based therapies and 2 chemotherapies
- In the exploratory analysis, improvement in m-OS benefit (14.5 vs 11.2mos.), PFS rates at 6/12/18mos. (45.6% vs 29.4%)/ (21.7% vs 8.4%)/ (14.4% vs 4.7%), OS rates at 12/18/24mos. (60.9% vs 47.1%)/ (39.2% vs 31.7%)/ (25.7% vs 21.1%), respectively, 92% were eligible for evaluation of OS
- The therapy also showed improved OS in HER2 IHC0 (m-OS: 13.6 vs 10.8mos.) and HER2-low groups (m-OS: 15.4 vs 11.5mos.) with no new safety signals, the discontinuation rate due to adverse reactions (6% vs 4%)
Ref: Gilead | Image: Gilead
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.